Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
ArchivedNational Institutes of Health
Description
This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities / Indian housing authorities
- Native American tribal organizations (other than Federally recognized)
- Nonprofits with 501(c)(3) status (other than higher education)
- Nonprofits without 501(c)(3) status (other than higher education)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Contact
NIH OER Webmaster<br/>OERWebmaster03@od.nih.gov
OERWebmaster03@od.nih.gov
- PostedNov 9, 2021
- ClosesNov 16, 2024
- Award ceiling$275,000
- CFDA93.865
Pro insight
Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.
Unlock with Pro